Watch as Virginia Kaklamani, MD, and E. Shelley Hwang, MD, discuss the latest breakthroughs in breast cancer care, including promising trials with the potential to lead to FDA approvals and a novel approach to treating DCIS. These insights from the San Antonio Breast Cancer Symposium highlight exciting progress in therapies and strategies shaping the future of breast oncology.
Source : https://pubmed.ncbi.nlm.nih.gov/38845834/
The requisite knowledge of late effects following OPS is still not available for unambiguous recommendations. This narrative review has elucidated the knowledge and has reached a conclusion based on review...
This review investigates shoulder morbidity following oncoplastic breast conserving surgery (OPS). Findings suggest that shoulder function after OPS is comparable to breast conserving surgery and mastectomy, though more research is needed.
Source : https://pubmed.ncbi.nlm.nih.gov/39290400/
This systematic review and meta-analysis indicated a pooled prevalence of 31% neuropathic pain following breast-conserving surgery of, with confidence interval ranging from 14% to 56%. The review did not provide...
This systematic review found a 31% pooled prevalence of neuropathic pain following breast-conserving surgery, with no conclusive evidence linking axillary procedures to the pain's occurrence.
Source : https://pubmed.ncbi.nlm.nih.gov/39294665/
The present review provides a comprehensive understanding of the molecular mechanisms, coupled with well-designed clinical trials and adherence to regulatory guidelines, which pave the way for nutrition-based combination therapies to...
This review highlights the potential of dietary phytomolecules in breast cancer treatment, focusing on their molecular mechanisms, combination therapy, novel drug delivery systems, and regulatory considerations for clinical application.
Source : https://pubmed.ncbi.nlm.nih.gov/38773552/
Clinicaltrials.gov: NCT04144309. Registered 12 June 2018.
This randomized trial found that infrared laser moxibustion (ILM) significantly reduced cancer-related fatigue in breast cancer survivors compared to a waitlist control, with promising but inconclusive results versus sham treatment.